Aspire BioScience is a private, development stage company focused on development of small-molecule therapeutics for safe, non-addictive treatment of a pain, PTSD and substance (e.g. opioid) use disorders. AspireBio’s two lead therapeutics, URB937 and URB597, were developed at the University of California, Irvine (UCI), and have significant, transformative clinical and commercial potential in diseases with substantial unmet medical needs.